Table 1.
Demographic and clinical characteristics
| Characteristics (N=79) | Mean (SD) |
|---|---|
| Age (year) | 56.7 (14.7) |
| Woman (n, %) | 68 (86) |
| Body mass index | 21.9 (3.3), N=74 |
| Current smoker (n, %) | 19 (24) |
| Symptom duration before MTX start (month) | 2.2 (5.7) |
| Anti-CCP positive (n, %) | 53 (67) |
| RF positive (n, %) | 66 (85) |
| DAS28 | 4.0 (1.1) |
| HAQ-DI | 0.894 (1.009) |
| AST (IU/mL) | 19 (5) |
| ALT (IU/mL) | 16 (8) |
| eGFR (mL/min) | 88 (26) |
| Other DMARDs use (n, %) | 7 (9) |
| Glucocorticoid use (n, %) | 6 (8) |
| NSAID use (n, %) | 27 (34) |
ALT, alanine transaminase; Anti-CCP, anti-cyclic citrullinated peptide; AST, aspartate transaminase; DAS28, Disease Activity Score for 28 joints; DMARDs, disease-modifying anti-rheumatic drugs; eGFR, estimated glomerular filtration rate; HAQ-DI, Health Assessment Questionnaire Disability Index; MTX, methotrexate; NSAID, non-steroid anti-inflammatory drug; RF, rheumatoid factor.